Akeso (FRA:4RY) EPS without NRI: €-0.15 (TTM As of Dec. 2025)


FRA:4RY Akeso Inc FRA:4RY
51 GF Score
Price €11.31
GF Value €16.81
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Akeso EPS without NRI?

Akeso FRA:4RY +0.22% 51 EPS without NRI is €-0.15 as of Dec. 2025. GuruFocus rates FRA:4RY with a GF Score™ of 51/100 and a GF Value™ of €16.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,166 Biotechnology companies, Akeso ranks worse than 64.32% on this metric.

Akeso's earnings per share without non-recurring items for the six months ended in Dec. 2025 was €-0.07. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Akeso's EPS without NRI or its related term are showing as below:

FRA:4RY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -96.4   Med: -21.35   Max: 26.1
Current: 5.6

During the past 8 years, Akeso's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 26.10% per year. The lowest was -96.40% per year. And the median was -21.35% per year.

FRA:4RY's 3-Year EPS without NRI Growth Rate is ranked worse than
64.32% of 1166 companies
in the Biotechnology industry
Industry Median: 16.65 vs FRA:4RY: 5.60

Akeso's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.

Akeso's EPS (Basic) for the six months ended in Dec. 2025 was €-0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.


Akeso  (FRA:4RY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Akeso EPS without NRI Related Terms


Akeso EPS without NRI Historical Data

* Premium members only.

The historical data trend for Akeso's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso EPS without NRI Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -0.19 -0.19 0.30 -0.08 -0.15

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.04 -0.04 -0.08 -0.07

FRA:4RY vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Akeso's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akeso PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Akeso's PE Ratio without NRI falls into.


FRA:4RY
51GF Score
Akeso Inc FRA:4RY
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akeso EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.15 mean?
Akeso (FRA:4RY) has a EPS without NRI of €-0.15 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Akeso and its competitors. According to the industry distribution chart, Akeso ranks #750 out of 1166 companies in the Biotechnology industry, placing it in the top 64.3%.
Is Akeso's EPS without NRI too high?
Akeso's current EPS without NRI is €-0.15. Based on the distribution chart, Akeso ranks #750 out of 1166 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Akeso has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akeso's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #750 out of 1166 companies for EPS without NRI. This places Akeso in the lower half of its industry. The industry median EPS without NRI is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Akeso and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akeso's current EPS without NRI is €-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Possible Value Trap. The stock's GF Value™ is €16.81, compared to a current price of €11.31 — trading 32.7% below its estimated fair value. The current EPS without NRI is €-0.15. Akeso's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Akeso (FRA:4RY), the current EPS without NRI is €-0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €11.31 is trading 32.7% below its estimated GF Value™ of €16.81. GuruFocus considers Akeso to be Possible Value Trap.

Key valuation signals for FRA:4RY:

  • EPS without NRI: €-0.15
  • GF Value™: €16.81 vs. price of €11.31 (32.7% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
51GF Score

Get the complete analysis for FRA:4RY

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.31
Price
€16.81
GF Value